451 related articles for article (PubMed ID: 20735821)
1. Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: A multicenter randomized trial evaluating the efficacy of Cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease.
Lee SP; Suh JW; Park KW; Lee HY; Kang HJ; Koo BK; Chae IH; Choi DJ; Rha SW; Bae JW; Cho MC; Kwon TG; Bae JH; Kim HS;
Trials; 2010 Aug; 11():87. PubMed ID: 20735821
[TBL] [Abstract][Full Text] [Related]
2. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial.
Suh JW; Lee SP; Park KW; Lee HY; Kang HJ; Koo BK; Cho YS; Youn TJ; Chae IH; Choi DJ; Rha SW; Bae JH; Kwon TG; Bae JW; Cho MC; Kim HS
J Am Coll Cardiol; 2011 Jan; 57(3):280-9. PubMed ID: 21232664
[TBL] [Abstract][Full Text] [Related]
3. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory interaction between calcium channel blocker and clopidogrel. -Efficacy of cilostazol to overcome it-.
Lee SP; Bae JW; Park KW; Rha SW; Bae JH; Suh JW; Chae IH; Cho MC; Kim HS
Circ J; 2011; 75(11):2581-9. PubMed ID: 21857144
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial.
Lee SW; Park SW; Kim YH; Yun SC; Park DW; Lee CW; Kang SJ; Park SJ; Lee JH; Choi SW; Seong IW; Lee NH; Cho YH; Shin WY; Lee SJ; Lee SW; Hyon MS; Bang DW; Choi YJ; Kim HS; Lee BK; Lee K; Park HK; Park CB; Lee SG; Kim MK; Park KH; Park WJ;
J Am Coll Cardiol; 2011 Mar; 57(11):1264-70. PubMed ID: 21392640
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of two different self-expanding nitinol stents for atherosclerotic femoropopliteal arterial disease (SENS-FP trial): study protocol for a randomized controlled trial.
Park SH; Rha SW; Choi CU; Kim EJ; Oh DJ; Cho YH; Choi WG; Lee SJ; Kim YH; Choi SH; Kim WH; Kim KC; Cho JH; Kim JH; Kim SM; Bae JH; Bong JM; Kang WY; Baek JY; Seo JB; Chung WY; Park MW; Her SH; Suh J; Kim MW; Kim YJ; Choi HJ; Soh JW;
Trials; 2014 Sep; 15():355. PubMed ID: 25208688
[TBL] [Abstract][Full Text] [Related]
7. Study design of the influence of SErotonin inhibition on patients with RENAl impairment or diabetes undergoing drug-eluting stent implantation (SERENADE) study: A multicenter, open-label, prospective, randomized study.
Lee SA; Suh JW; Park JJ; Yoon CH; Cho YS; Youn TJ; Chae IH; Kim HS; Kim SH; Choi DJ
Contemp Clin Trials; 2015 Jul; 43():20-4. PubMed ID: 25891091
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial.
Helft G; Le Feuvre C; Georges JL; Carrie D; Leclercq F; Eltchaninoff H; Furber A; Prunier F; Sebagh L; Cattan S; Cayla G; Vicaut E; Metzger JP
Trials; 2013 Feb; 14():56. PubMed ID: 23433461
[TBL] [Abstract][Full Text] [Related]
9. The Effect of Cilostazol on the Angiographic Outcome of Drug-Eluting Coronary Stents Angiographic Analysis of the CILON-T (Influence of CILostazol-Based Triple Antiplatelet Therapy ON Ischemi Complication after Drug-Eluting StenT Implantation) Trial.
Suh JW; Lee SP; Park K; Kang HJ; Koo BK; Cho YS; Youn TJ; Chae IH; Choi DJ; Rha SW; Bae JH; Kwon TG; Bae JW; Cho MC; Kim HS
Int Heart J; 2017 Dec; 58(6):853-860. PubMed ID: 29118299
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials.
Chen J; Meng H; Xu L; Liu J; Kong D; Chen P; Gong X; Bai J; Zou F; Yang Z; Li C; Eikelboom JW
J Thromb Thrombolysis; 2015 Jan; 39(1):23-34. PubMed ID: 24869717
[TBL] [Abstract][Full Text] [Related]
11. A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial.
Wenaweser P; Eshtehardi P; Abrecht L; Zwahlen M; Schmidlin K; Windecker S; Meier B; Haeberli A; Hess OM
Thromb Haemost; 2010 Sep; 104(3):554-62. PubMed ID: 20664903
[TBL] [Abstract][Full Text] [Related]
12. Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Gupta R; Kirtane AJ; Ozan MO; Witzenbichler B; Rinaldi MJ; Metzger DC; Weisz G; Stuckey TD; Brodie BR; Mehran R; Ben-Yehuda O; Stone GW
Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28288963
[TBL] [Abstract][Full Text] [Related]
13. Detection of clopidogrel hyporesponsiveness using a point-of-care assay and the impact of additional cilostazol administration after coronary stent implantation in diabetic patients.
Yang TH; Kim DI; Kim DK; Jang JS; Kim U; Seol SH; Kim DK; Hong GR; Park JS; Shin DG; Kim YJ; Cho YK; Nam CW; Hur SH; Kim KB; Kim DS
Korean J Intern Med; 2011 Jun; 26(2):145-52. PubMed ID: 21716590
[TBL] [Abstract][Full Text] [Related]
14. It Is Not Mandatory to Use Triple Rather Than Dual Anti-Platelet Therapy After a Percutaneous Coronary Intervention With a Second-Generation Drug-Eluting Stent.
Kim JY; Choi YS; Kwon A; Chung WB; Park CS; Kim HY; Chang K; Lee MY; Chung WS; Seung KB
Medicine (Baltimore); 2015 Nov; 94(46):e2062. PubMed ID: 26579817
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 1-Year Outcomes of Triple (Aspirin + Clopidogrel + Cilostazol) Versus Dual Antiplatelet Therapy (Aspirin + Clopidogrel + Placebo) After Implantation of Second-Generation Drug-Eluting Stents into One or More Coronary Arteries: from the DECREASE-PCI Trial.
Lee CH; Lee JY; Park GM; Lee SW; Kim HS; Choi YJ; Nam CW; Cho JH; Shin WY; Seo JB; Choi SW; Lee JH; Min PK; Her SH; Lee PH; Ahn JM; Park DW; Kang SJ; Kim YH; Lee CW; Park SW; Park SJ
Am J Cardiol; 2018 Feb; 121(4):423-429. PubMed ID: 29273207
[TBL] [Abstract][Full Text] [Related]
16. Triple versus dual antiplatelet therapy after percutaneous coronary intervention for coronary bifurcation lesions: results from the COBIS (COronary BIfurcation Stent) II Registry.
Song PS; Song YB; Yang JH; Hahn JY; Choi SH; Choi JH; Lee SH; Kim HS; Jang Y; Seung KB; Oh JH; Gwon HC
Heart Vessels; 2015 Jul; 30(4):458-68. PubMed ID: 24682436
[TBL] [Abstract][Full Text] [Related]
17. Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study.
Stuckey TD; Kirtane AJ; Brodie BR; Witzenbichler B; Litherland C; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Gurbel PA; Mehran R; Généreux P; Ben-Yehuda O; Simonton CA; Stone GW;
JACC Cardiovasc Interv; 2017 Aug; 10(16):1607-1617. PubMed ID: 28780034
[TBL] [Abstract][Full Text] [Related]
18. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry).
Lee SW; Park SW; Yun SC; Kim YH; Park DW; Kim WJ; Lee JY; Lee CW; Hong MK; Kim JJ; Park SJ
Am Heart J; 2010 Feb; 159(2):284-291.e1. PubMed ID: 20152228
[TBL] [Abstract][Full Text] [Related]
19. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients).
Lee SW; Park SW; Kim YH; Yun SC; Park DW; Lee CW; Hong MK; Kim HS; Ko JK; Park JH; Lee JH; Choi SW; Seong IW; Cho YH; Lee NH; Kim JH; Chun KJ; Park SJ
J Am Coll Cardiol; 2008 Mar; 51(12):1181-7. PubMed ID: 18355656
[TBL] [Abstract][Full Text] [Related]
20. Platelet inhibition by adjunctive cilostazol suppresses the frequency of cerebral ischemic lesions after carotid artery stenting in patients with carotid artery stenosis.
Nakagawa I; Wada T; Park HS; Nishimura F; Yamada S; Nakagawa H; Kichikawa K; Nakase H
J Vasc Surg; 2014 Mar; 59(3):761-7. PubMed ID: 24239116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
